The Heart Cells Foundation, at Barts Health NHS Trust, is funding the pioneering research and development of a revolutionary and potentially life-saving treatment that uses a patient’s own adult stem cells to repair the heart. Helping those with heart disease, whether they have suffered a heart attack or have developed a weak heart for other reasons. Planning for Phase 3 of the Trials has now begun, alongside the opening of the Compassionate Treatment Programme.
REGENERATE-IHD, REGENERATE-AMI, REGENERATE-DCM and BAMI .
Trial 1 – Regenerate IHD, treated patients suffering from heart failure from Ischeamic heart disease. The trial has now finished recruitment and follow-up. We have received extremely positive feedback from patients who have felt a marked improvement in their health and everyday lives. We have analysed the data and it has shown positive results towards patients treated with stem cells. The results to be published in medical literature. Setting up a Compassionate Unit to offer treatment to patients suffering with a similar condition.
Trial 2 – Regenerate AMI, treated patients within 24 hours of suffering a heart attack. Now analysed the data to be published in medical literature.
Trial 3 – Regenerate DCM, treated patients with congenital and inherited heart failure. The results, which we are in the process of publishing in the medical press, have shown a positive benefit for patients treated with stem cells over those treated with a placebo.
Trial 4 – BAMI, the biggest and most ambitious trial to date funded by the European Union as a result of the Heart Cells Foundation trials. Recruiting 3000 patients from across the UK and Europe. Similar to the criteria of the Regenerate AMI trial, the BAMI trial is treating patients who have recently suffered a heart attack, injecting stem cells into the heart a couple of days later.
BAMI – European Update
The World’s Largest Adult Stem Cell Heart Attack Trial
BAMI as a result of the Heart Cells Foundation Trial currently has 29 hospitals actively recruiting patients on the study across 8 countries in Europe, 2 in the UK and soon to begin in Switzerland. BAMI is the largest study ever conducted in the field of regenerative medicine.